126716-23-2

Basic information

• Product Name: methyl 5-O-benzyl-2-O-tosyl-3-fluoro-3-deoxy-α-D-arabino-furanoside
• Synonyms: methyl 5-O-benzyl-2-O-tosyl-3-fluoro-3-deoxy-α-D-arabino-furanoside
• CAS NO: 126716-23-2
• Molecular Weight: 410.463
• Mol File: 126716-23-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 5-O-benzyl-2-O-tosyl-3-fluoro-3-deoxy-α-D-arabino-furanoside(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-O-benzyl-2-O-tosyl-3-fluoro-3-deoxy-α-D-arabino-furanoside(126716-23-2)
• EPA Substance Registry System: methyl 5-O-benzyl-2-O-tosyl-3-fluoro-3-deoxy-α-D-arabino-furanoside(126716-23-2)

Safety Data

• Hazardous Substances Data: 126716-23-2(Hazardous Substances Data)

Upstream product

• 7045-40-1 Methyl 3,5-O-Isopropylidene-α-D-xylofuranoside 
• 26532-10-5 methyl 2,3-anhydro-α-D-lyxofuranoside 
• 14980-09-7 methyl 5-O-benzyl-3-fluoro-3-deoxy-α-D-arabino-furanoside 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 123484-12-8 ((2R,3R,4S)-5-acetoxy-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate 
• 126716-27-6 methyl 2,5-di-O-benzoyl-3-fluoro-3-deoxy-α-D-ribofuranoside 
• 126737-61-9 methyl 2-O-benzoyl-3-fluoro-3-deoxy-α-D-ribofuranoside 
• 133776-16-6 C₃₆H₄₂FN₅O₇ 
• 133776-15-5 C₃₆H₄₂FN₅O₇ 
• 112668-60-7 N6-benzoyl-9-(2'-O-benzoyl-3'-deoxy-3'-fluoro-β-D-ribofuranosyl)adenine 
• 133776-14-4 C₂₆H₂₂FN₅O₇ 
• 133776-12-2 C₂₃H₁₉FN₂O₇ 
• 112668-58-3 1-(2,5-di-O-benzoyl-3-deoxy-3-fluoro-β-D-ribofuranosyl)uracil 
• 133776-13-3 C₂₃H₂₀FN₃O₆ 
• 123402-21-1 2-amino-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purine-6-one 
• 123402-20-0 3'-deoxy-3'-fluorocytidine 
• 75059-22-2 (2R,3S,4S,5R)-2-(6-amino-9H-purine-9-yl)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol 
• 124939-87-3 methyl 5-O-benzyl-2-O-benzoyl-3-fluoro-3-deoxy-α-D-ribofuranoside 

Relevant articles and documents

NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).